Servier to Acquire Agios' Oncology Business for ~$2B

Share this


Servier to Acquire Agios' Oncology Business for ~$2B


  • Agios to receive ~$1.8B upfront in cash & ~$200M as regulatory milestones for Vorasidenib along with 5% royalties on sales of Tibsovo in the US from transaction close through the loss of exclusivity and 15% royalties on sales of vorasidenib in the US from first commercial sale through the loss of exclusivity
  • The acquisition is expected to close in Q2’21. The acquisition allows Servier to strengthen its product portfolio and drug development pipeline in oncology
  • The transaction includes the transfer of Agios' oncology portfolio and associated employees- including its Tibsovo and pipeline and clinical programs- including vorasidenib

 ­ Ref: PRNewswire  | Image: Enzo Life Sciences

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions